{"entity":{"id":"dung-le","kind":"person","name":"Dung T. Le","aka":[],"tldr":"First author of the studies that showed mismatch-repair-deficient tumours respond to PD-1 blockade regardless of origin.","summary":"Dung T. Le is Professor of Oncology and Co-Director of GI Cancer Immunotherapy at Johns Hopkins Hospital and the Sidney Kimmel Comprehensive Cancer Center. She is known as first author of the studies showing that mismatch-repair-deficient tumours respond to PD-1 blockade regardless of where they arise, leading the KEYNOTE-016 study and its extension that established pembrolizumab's tissue-agnostic activity. Her selected paper reports PD-1 blockade in tumours with mismatch-repair deficiency. She also works on GVAX and pancreatic cancer vaccines in colorectal and pancreatic cancer.","asOf":"2026-09-08","links":[{"label":"Hopkins profile","url":"https://www.hopkinsmedicine.org/profiles/details/dung-le"},{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Le%20DT%5BAuthor%5D"}],"tags":[],"related":[],"cancers":["colorectal","pancreatic"],"sections":[],"technologies":[],"targets":["pd1"],"drugs":["pembrolizumab"],"companies":[],"institutions":["johns-hopkins"],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"role":"Professor of Oncology; Co-Director, GI Cancer Immunotherapy","institutionId":"johns-hopkins","specialisms":["MSI-high cancers","Pancreatic cancer immunotherapy","Cancer vaccines"],"profiles":[{"label":"Hopkins profile","url":"https://www.hopkinsmedicine.org/profiles/details/dung-le"},{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Le%20DT%5BAuthor%5D"}],"papers":[{"title":"PD-1 blockade in tumors with mismatch-repair deficiency","journal":"New England Journal of Medicine","year":2015,"url":"https://doi.org/10.1056/NEJMoa1500596","doi":"10.1056/NEJMoa1500596"},{"title":"KEYNOTE-177: pembrolizumab instead of chemotherapy as first treatment for mismatch-repair-deficient metastatic colorectal cancer","journal":"New England Journal of Medicine","year":2020,"url":"https://doi.org/10.1056/NEJMoa2017699","doi":"10.1056/NEJMoa2017699"},{"title":"Le 2017: mismatch-repair deficiency predicts response to PD-1 blockade across twelve tumour types, leading to the first tissue-agnostic drug approval","journal":"Science","year":2017,"url":"https://doi.org/10.1126/science.aan6733","doi":"10.1126/science.aan6733"}],"orcid":"0000-0002-2110-7697"},"route":"/people/dung-le/","neighbours":{"cancer":[{"id":"colorectal","kind":"cancer","name":"Colorectal cancer","route":"/cancers/colorectal/"},{"id":"msi-high-pdac","kind":"cancer","name":"Mismatch repair deficient (MSI-high) pancreatic ductal adenocarcinoma","route":"/cancers/msi-high-pdac/"},{"id":"pancreatic","kind":"cancer","name":"Pancreatic ductal adenocarcinoma","route":"/cancers/pancreatic/"}],"target":[{"id":"pd1","kind":"target","name":"PD-1","route":"/targets/pd1/"}],"drug":[{"id":"pembrolizumab","kind":"drug","name":"Pembrolizumab","route":"/drugs/pembrolizumab/"}],"institution":[{"id":"johns-hopkins","kind":"institution","name":"Johns Hopkins Hospital / Sidney Kimmel Comprehensive Cancer Center","route":"/institutions/johns-hopkins/"}],"roadmap":[{"id":"colorectal-roadmap","kind":"roadmap","name":"Colorectal cancer roadmap: from the adenoma-carcinoma sequence and the first screening trials to total mesorectal excision, oxaliplatin, RAS testing, immunotherapy for mismatch repair-deficient disease, ctDNA-guided treatment and organ preservation","route":"/roadmaps/colorectal-roadmap/"}],"paper":[{"id":"paper-keynote-158-pembrolizumab-msi-high-noncolorectal-jco-2020","kind":"paper","name":"KEYNOTE-158: pembrolizumab in non-colorectal high microsatellite instability or mismatch repair-deficient cancer","route":"/key-papers/paper-keynote-158-pembrolizumab-msi-high-noncolorectal-jco-2020/"},{"id":"paper-keynote-177-nejm-2020","kind":"paper","name":"KEYNOTE-177: pembrolizumab instead of chemotherapy as first treatment for mismatch-repair-deficient metastatic colorectal cancer","route":"/key-papers/paper-keynote-177-nejm-2020/"},{"id":"paper-le-mmr-deficiency-pd1-nejm-2015","kind":"paper","name":"Le 2015: PD-1 blockade works in tumours with mismatch-repair deficiency, whatever the organ","route":"/key-papers/paper-le-mmr-deficiency-pd1-nejm-2015/"},{"id":"paper-le-mmr-deficiency-science-2017","kind":"paper","name":"Le 2017: mismatch-repair deficiency predicts response to PD-1 blockade across twelve tumour types, leading to the first tissue-agnostic drug approval","route":"/key-papers/paper-le-mmr-deficiency-science-2017/"}]}}